Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus SIRT in hepatocellular carcinoma
2017-000232-34Phase 2Completed
- Sponsor
- Clínica Universidad de Navarra
- Start
- Jun 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab in hepatocellular carcinoma (HCC), sponsored by Clínica Universidad de Navarra. Primary endpoints: Rate and type of adverse events, Serious adverse events and 2 more. Started Jun 2017; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on 2017-000232-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000232-34.